Q-omics provides the consensus-scored FUCA2 profile across patient tissues and cancer cell-line models. FUCA2 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FUCA2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FUCA2 RNA expression shows 19,464 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where FUCA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUCA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUCA2 survival associations across molecular data types. FUCA2 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUCA2 RNA expression–survival associations across cancer types. High FUCA2 expression shows unfavorable associations in LUAD, LIHC, KICH, OV, MESO and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FUCA2 RNA expression.
This table summarizes FUCA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FUCA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUCA2 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, BLCA, KIRC and STAD. The HNSC box plot shows higher FUCA2 RNA expression in tumor versus normal tissue (log2 FC = +1.373, t-test p < 0.001).
This table shows molecular features associated with FUCA2 in patient tissues and cancer cell lines. In patient samples, FUCA2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FUCA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
